PCO 371

Drug Profile

PCO 371

Alternative Names: PCO371

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Calcium regulators; Small molecules
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypoparathyroidism

Most Recent Events

  • 03 Dec 2015 Chugai Pharmaceutical terminates a phase-I clinical trial in Hypoparathyroidism (In volunteers) in USA (PO) (NCT02475616)
  • 01 Jun 2015 Phase-I clinical trials in Hypoparathyroidism (In volunteers) in USA (PO) (NCT02475616)
  • 30 May 2015 Chugai Pharmaceutical plans a phase I trial in Healthy volunteers in USA (PO) (NCT02475616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top